Zanotti KM - Search Results

1

An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).

Fader AN, Starks D, Gehrig PA, Secord AA, Frasure HE, O'Malley DM, Tuller ER, Rose PG, Havrilesky LJ, Moore KN, Huh WK, Axtell AE, Kelley JL, Zanotti KM; UPSC Consortium. Fader AN, et al. Among authors: zanotti km. Gynecol Oncol. 2009 Nov;115(2):244-8. doi: 10.1016/j.ygyno.2009.07.030. Epub 2009 Aug 26. Gynecol Oncol. 2009. PMID: 19712966

2

Analysis of allelic imbalance on chromosome 17p13 in stage I and stage II epithelial ovarian cancers.

Wiper DW, Zanotti KM, Kennedy AW, Belinson JL, Casey G. Wiper DW, et al. Among authors: zanotti km. Gynecol Oncol. 1998 Oct;71(1):77-82. doi: 10.1006/gyno.1998.5110. Gynecol Oncol. 1998. PMID: 9784323

3

The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.

Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. Zanotti KM, et al. Gynecol Oncol. 1999 Aug;74(2):272-7. doi: 10.1006/gyno.1999.5444. Gynecol Oncol. 1999. PMID: 10419744

4

Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.

Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. Zanotti KM, et al. Gynecol Oncol. 2000 Nov;79(2):211-5. doi: 10.1006/gyno.2000.5958. Gynecol Oncol. 2000. PMID: 11063646

5

Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity.

Markman M, Zanotti K, Kulp B, Peterson G, Markman M. Markman M, et al. Gynecol Oncol. 2003 Jun;89(3):514-6. doi: 10.1016/s0090-8258(03)00155-0. Gynecol Oncol. 2003. PMID: 12798720

6

Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis.

Markman M, Zanotti K, Webster K, Belinson J, Rose P. Markman M, et al. Oncology (Williston Park). 2003 May;17(5 Suppl 5):34-5. Oncology (Williston Park). 2003. PMID: 12800604 Clinical Trial.

7

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.

Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Markman M, et al. Gynecol Oncol. 2003 Sep;90(3):593-6. doi: 10.1016/s0090-8258(03)00399-8. Gynecol Oncol. 2003. PMID: 13678730 Clinical Trial.

8

Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia.

Markman M, Elson P, Kulp B, Peterson G, Zanotti K, Webster K, Belinson J. Markman M, et al. Gynecol Oncol. 2003 Oct;91(1):118-22. doi: 10.1016/s0090-8258(03)00517-1. Gynecol Oncol. 2003. PMID: 14529670 Clinical Trial.

9

Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.

Markman M, Zanotti K, Webster K, Peterson G, Kulp B, Belinson J. Markman M, et al. Gynecol Oncol. 2003 Dec;91(3):573-6. doi: 10.1016/j.ygyno.2003.08.001. Gynecol Oncol. 2003. PMID: 14675679

10

Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.

Escobar PF, Markman M, Rose P, Zanotti K, Webster K, Belinson J. Escobar PF, et al. Gynecol Oncol. 2004 Jan;92(1):192-6. doi: 10.1016/j.ygyno.2003.10.003. Gynecol Oncol. 2004. PMID: 14751157 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

68 results

Search Page

Filters